Vosaroxin: A new valuable tool with the potential to replace anthracyclines in the treatment of AML?

Ciara Freeman, Niamh Keane, Ronan T Swords, Francis Giles

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Despite significant advances in diagnosis and supportive care, the majority of patients diagnosed with acute myeloid leukemia (AML) ultimately die of their disease. Standard intensive induction treatment continues to comprise cytarabine and a topoisomerase II (topo II) poison, usually an anthracycline. Vosaroxin, a novel first-in-class quinolone derivative has been developed for use in the treatment of AML as a new-generation topo II inhibitor. It has shown promising activity as a monotherapy and also in combination with intermediate dose cytarabine (IDAC) in relapsed and refractory patient cohorts with minimal toxicity and good tolerability. Areas covered: The authors discuss the mechanism of action of vosaroxin, the pharmacokinetics, safety and tolerability, preclinical and clinical trial results available as well as areas of ongoing research. Expert opinion: Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. It evades common resistance pathways of p53 and P-glycoprotein (P-gp) and does not appear to generate significant reactive oxygen species (ROS) associated with these agents. Should future investigation confirm its efficacy and advantageous safety profile, vosaroxin could potentially replace older generation topoisomerase poisons in the treatment of AML and other malignant conditions.

Original languageEnglish
Pages (from-to)1417-1427
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number10
DOIs
StatePublished - Jul 1 2013

Fingerprint

Anthracyclines
Acute Myeloid Leukemia
Poisons
Cytarabine
Topoisomerase II Inhibitors
Safety
Type II DNA Topoisomerase
Quinolones
Cytotoxins
Expert Testimony
P-Glycoprotein
Therapeutics
Reactive Oxygen Species
Patient Care
Pharmacokinetics
Clinical Trials
vosaroxin
Research

Keywords

  • Acute myeloid leukemia
  • AG-7352
  • Anthracyclines
  • Ara-C
  • Cytarabine
  • Naphthyridine analog
  • P-glycoprotein
  • Quinolones
  • SNS-595
  • Topoisomerase II
  • Voreloxin
  • Vosaroxin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Vosaroxin : A new valuable tool with the potential to replace anthracyclines in the treatment of AML? / Freeman, Ciara; Keane, Niamh; Swords, Ronan T; Giles, Francis.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 10, 01.07.2013, p. 1417-1427.

Research output: Contribution to journalArticle

Freeman, Ciara ; Keane, Niamh ; Swords, Ronan T ; Giles, Francis. / Vosaroxin : A new valuable tool with the potential to replace anthracyclines in the treatment of AML?. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 10. pp. 1417-1427.
@article{0d2f8e92ac7344ebb42e815d0934ba0e,
title = "Vosaroxin: A new valuable tool with the potential to replace anthracyclines in the treatment of AML?",
abstract = "Introduction: Despite significant advances in diagnosis and supportive care, the majority of patients diagnosed with acute myeloid leukemia (AML) ultimately die of their disease. Standard intensive induction treatment continues to comprise cytarabine and a topoisomerase II (topo II) poison, usually an anthracycline. Vosaroxin, a novel first-in-class quinolone derivative has been developed for use in the treatment of AML as a new-generation topo II inhibitor. It has shown promising activity as a monotherapy and also in combination with intermediate dose cytarabine (IDAC) in relapsed and refractory patient cohorts with minimal toxicity and good tolerability. Areas covered: The authors discuss the mechanism of action of vosaroxin, the pharmacokinetics, safety and tolerability, preclinical and clinical trial results available as well as areas of ongoing research. Expert opinion: Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. It evades common resistance pathways of p53 and P-glycoprotein (P-gp) and does not appear to generate significant reactive oxygen species (ROS) associated with these agents. Should future investigation confirm its efficacy and advantageous safety profile, vosaroxin could potentially replace older generation topoisomerase poisons in the treatment of AML and other malignant conditions.",
keywords = "Acute myeloid leukemia, AG-7352, Anthracyclines, Ara-C, Cytarabine, Naphthyridine analog, P-glycoprotein, Quinolones, SNS-595, Topoisomerase II, Voreloxin, Vosaroxin",
author = "Ciara Freeman and Niamh Keane and Swords, {Ronan T} and Francis Giles",
year = "2013",
month = "7",
day = "1",
doi = "10.1517/14656566.2013.799138",
language = "English",
volume = "14",
pages = "1417--1427",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Vosaroxin

T2 - A new valuable tool with the potential to replace anthracyclines in the treatment of AML?

AU - Freeman, Ciara

AU - Keane, Niamh

AU - Swords, Ronan T

AU - Giles, Francis

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Introduction: Despite significant advances in diagnosis and supportive care, the majority of patients diagnosed with acute myeloid leukemia (AML) ultimately die of their disease. Standard intensive induction treatment continues to comprise cytarabine and a topoisomerase II (topo II) poison, usually an anthracycline. Vosaroxin, a novel first-in-class quinolone derivative has been developed for use in the treatment of AML as a new-generation topo II inhibitor. It has shown promising activity as a monotherapy and also in combination with intermediate dose cytarabine (IDAC) in relapsed and refractory patient cohorts with minimal toxicity and good tolerability. Areas covered: The authors discuss the mechanism of action of vosaroxin, the pharmacokinetics, safety and tolerability, preclinical and clinical trial results available as well as areas of ongoing research. Expert opinion: Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. It evades common resistance pathways of p53 and P-glycoprotein (P-gp) and does not appear to generate significant reactive oxygen species (ROS) associated with these agents. Should future investigation confirm its efficacy and advantageous safety profile, vosaroxin could potentially replace older generation topoisomerase poisons in the treatment of AML and other malignant conditions.

AB - Introduction: Despite significant advances in diagnosis and supportive care, the majority of patients diagnosed with acute myeloid leukemia (AML) ultimately die of their disease. Standard intensive induction treatment continues to comprise cytarabine and a topoisomerase II (topo II) poison, usually an anthracycline. Vosaroxin, a novel first-in-class quinolone derivative has been developed for use in the treatment of AML as a new-generation topo II inhibitor. It has shown promising activity as a monotherapy and also in combination with intermediate dose cytarabine (IDAC) in relapsed and refractory patient cohorts with minimal toxicity and good tolerability. Areas covered: The authors discuss the mechanism of action of vosaroxin, the pharmacokinetics, safety and tolerability, preclinical and clinical trial results available as well as areas of ongoing research. Expert opinion: Vosaroxin has shown efficacy as a novel cytotoxic agent, and despite a similar mechanism of action has significant advantages over anthracyclines. It evades common resistance pathways of p53 and P-glycoprotein (P-gp) and does not appear to generate significant reactive oxygen species (ROS) associated with these agents. Should future investigation confirm its efficacy and advantageous safety profile, vosaroxin could potentially replace older generation topoisomerase poisons in the treatment of AML and other malignant conditions.

KW - Acute myeloid leukemia

KW - AG-7352

KW - Anthracyclines

KW - Ara-C

KW - Cytarabine

KW - Naphthyridine analog

KW - P-glycoprotein

KW - Quinolones

KW - SNS-595

KW - Topoisomerase II

KW - Voreloxin

KW - Vosaroxin

UR - http://www.scopus.com/inward/record.url?scp=84878859644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878859644&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.799138

DO - 10.1517/14656566.2013.799138

M3 - Article

C2 - 23688047

AN - SCOPUS:84878859644

VL - 14

SP - 1417

EP - 1427

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -